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Facts and Demographics
Acute Myeloid Leukemia, or AML, also known as acute
myelogenous leukemia and acute nonlympocytic leukemia (ANLL),
is a disease that is estimated to affect 21,380 people in the U.S.,
killing 10,590 this year alone according to the National Institute of
Cancer (NIC, 2017).
AML is a disease of the myeloid cells in the bone marrow. These
cells proliferate uncontrollably and lose their ability to
differentiate to functioning components of the blood (Sykes et al
p. 989).
AML has a 26.6% 5-year survival rate, and 5-10-month survival
rate for patients who cannot tolerate the high intensity
chemotherapy that is often required for complete remission (Cruz
et al p. 53). Relapse rate is reported to be 30% to 40% within the
first three years (Cruz et al p. 54).

Acute Myeloid Leukemia
Adrianna M. Wayble, R.N., B.S.N.
Otterbein University
NURS 5330 Summer 2017
Treatment
The goal of treatment for AML, which can be either a combination of
chemotherapy and/or radiation alone, or with a stem cell transplant, is
complete remission. Partial remission has shown to have no benefit to survival
(www.cancer.gov, 2017).
Treatment is intensive to endure. Patients must first go through chemotherapy
and/or radiation to achieve complete remission status, followed by another
course of high intensity chemotherapy and/or radiation to prepare for
hematopoietic stem cell transplantation (HSCT). Patients receive stem cells
from a donor (allogeneic or allo-HSCT) (Mosseso, p. 22).

The goal of HSCT is to have engraftment of the donor cells, which will begin to
produce healthy cells. Engraftment of neutrophils can take up to 20 days, and
The disease process is multi-faceted, with many factors that are
believed to cause AML, from genetics to environmental exposures engraftment of platelets can take up to eight weeks (Mosseso, p. 25). The ANC,
or absolute neutrophil count must be at least 500/mm3 for engraftment.
(Wang & Bailey, 2016).
Platelet count must be at least 20,000 platelets per microliter for platelet
engraftment (Mosseso, p. 25).
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Genetic Discoveries
Genetic factors play an important role in
both the diagnosis and the treatment of
AML. It has been widely accepted that
genetic mutations, specifically translocations,
have an important impact on disease
presentation and treatment (Ohgami &
Arber, pp. 122-123).
The average AML genome contains
approximately 400 mutations (Link, Wolff &
Wolff, p. 409).
Billions of dollars were spent to first map the
human genome, something that can be done
in four to six weeks now, at a cost of $10,000
to $20,000 (Link, Wolff & Wolff, p. 410).

The first AML genome was mapped in 2008,
and since then dozens of mutations have
been discovered. (Link, Wolff & Wolff, p.
410). Mutations discovered are not “driver”
mutations, in that they do not cause the
Complications
stem cells to start mutating. Rather they are
AML patients who receive allo-HSCT have complications related to their body’s
“background” mutations, in that they can
defense against the foreign cells (Mosseso, p. 23). Immunosuppressive drugs are
help predict outcomes and relapses (Link,
given to prevent rejection, or patients may receive a combination of
Wolff & Wolff p. 409).
immunosuppressive drugs and T cell removal from donor cells (Mosseso, p. 24-25). Specific gene mutations, such as the RUNX1Complications also arise from pancytopenia secondary to intensive chemotherapy RUNXT1 (10-20% of cases), CBFB-MYH11 (510% of cases), PML-RARA (10-20% of cases
regimens. Patients are at a high risk for infection and bleeding. They need blood
transfusions and antibiotic coverage (WHO, 2014 p. 11). Of note, cardiotoxicity is a (Ohgami & Arber pp. 123-124).
Deletions and multiple translocations prove a
potential side effect of the chemotherapies daunorubicin and idarubicin. Central
nervous system toxicity is a side effect of cytarabine. Patients can develop severe poor prognosis (Ohgami & Arber p. 124).
diarrhea and mucositis secondary to chemotherapy effects as well (WHO, 2014 p. The World Health Organization distinguishes
11).
AML by the genetic composition of AML. This

Graft versus host disease (GVHD) can be a severe chronic or acute process. T cells
by the donor activate an immune response in the recipient, which results in an
inflammatory response, causing GVHD. Getting the best possible match of major
Illustration of differentiation of blood stem cells. Myeloid stem cells histocompatibility antigens is beneficial in curtailing GVHD (Sairafi et al, p. 1).
differentiate into many different specialized cells, such as red blood Lastly, patients suffer from an enormous amount of emotional and physical stress
cells, platelets, and granulocytes. Figure from the National Cancer
both during and after treatment. Patients report negative side effects, including
Institute (NIH, 2017).
both the emotional and financial burden of treatment, as well as long-term effects
of treatment (Ghodraty-Jabloo et al, pp. 2037-2041)

guides providers to determine the most
appropriate plan for patients (Wang & Bailey,
p. 1215).
Treatment plans are tailored to the specific
type of genetic mutations and abnormalities
for improved outcomes (Wang & Bailey, p.
1215).

ACUTE MYELOGENOUS LEUKEMIA AND ACUTE
PROMYELOCYTIC LEUKEMIA. Union for
International Cancer Control 2014 Review of
Cancer Medicines on the WHO List of Essential
Medicines. The World Health Organization.
Retrieved from
http://www.who.int/selection_medicines/com
mittees/expert/20/applications/AML_APL.pdf
Adult Acute Myeloid Leukemia Treatment
(PDQ®)–Health Professional Version. National
Cancer Institute. Retrieved from
https://www.cancer.gov/types/leukemia/hp/ad
ult-aml-treatment-pdq, Last updated January
20, 2017.
Cruz, N. M., Mencia-Trinchant, N., Hassane, D.
C., & Guzman, M. L. (2017). Minimal residual
disease in acute myelogenous leukemia.
International Journal Of Laboratory
Hematology, 3953-60. doi:10.1111/ijlh.12670
Ghodraty-Jabloo, V., Alibhai, S., Breunis, H.,
Puts, M., Alibhai, S. H., & Puts, M. E. (2016).
Keep your mind off negative things: coping with
long-term effects of acute myeloid leukemia
(AML). Supportive Care In Cancer, 24(5), 20352045. doi:10.1007/s00520-015-3002-4
National Cancer Institute (NIH). Chronic
Myelogenous Leukemia Treatment (PDQ®)–
Patient Version.
https://www.cancer.gov/types/leukemia/patie
nt/cml-treatment-pdq. Last updated March 6,
2017.
Ohgami, R. S., & Arber, D. A. (2015). The
diagnostic and clinical impact of genetics and
epigenetics in acute myeloid leukemia.
International Journal Of Laboratory
Hematology, 37122-132. doi:10.1111/ijlh.12367
Mosesso, K. (2015). Adverse Late and LongTerm Treatment Effects in Adult Allogeneic
Hematopoietic Stem Cell Transplant Survivors.
American Journal Of Nursing, 115(11), 22-45.
doi:10.1097/01.NAJ.0000473312.17572.29
Link, D. C. (2012). Molecular genetics of AML.
Best Practice & Research. Clinical Haematology,
25(4), 409-414. doi:10.1016/j.beha.2012.10.002
Sairafi, D., Stikvoort, A., Gertow, J., Mattsson,
J., & Uhlin, M. (2016). Donor Cell Composition
and Reactivity Predict Risk of Acute Graftversus-Host Disease after Allogeneic
Hematopoietic Stem Cell Transplantation.
Journal Of Immunology Research,
20165601204.
Sykes, S. M., Kokkaliaris, K. D., Milsom, M. D.,
Levine, R. L., & Majeti, R. (2015). Clonal
evolution of preleukemic hematopoietic stem
cells in acute myeloid leukemia. Experimental
Hematology, 43(12), 989-992.
doi:10.1016/j.exphem.2015.08.012
Wang, M. L., & Bailey, N. G. (2015). Acute
Myeloid Leukemia Genetics. Archives Of
Pathology & Laboratory Medicine, 139(10),
1215-1223. doi:10.5858/arpa.2015-0203-RA

